Dr. Percival is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-598-6190
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
Stanford University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2009 - Present
WA State Medical License 2015 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Start of enrollment: 2016 Sep 22
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Nov 30
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Start of enrollment: 2023 Dec 18
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, Harry P Erba, Eliana Dietrich
Leukemia. 2025-01-27 - Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.Noam E Kopmar, Xiaoyu Qu, Yajuan Liu, Ted A Gooley, Cristina M Ghiuzeli
Leukemia & Lymphoma. 2025-01-01 - Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.Khushboo V Pal, Megan Othus, Zahra Ali, Katherine Russell, Carole Shaw
Blood Advances. 2024-12-24
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Mary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast CountMary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...Mary-Elizabeth M. Percival, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Clinical Challenge: Hematologic Malignancy and COVID-19June 17th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
